The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

26 Nov 2010 07:00

26 November 2010 Sterling Green Group Plc ("Sterling Green" or "the Company") Half-yearly results for the six month period ended 30 September 2010 Highlights * Total revenue increased to £1.32 million (2009: £1.14 million) * Revenue from debt management services increased by 20 per cent to £1.25 million (2009: £1.05 million) * Profit before and after taxation increased to £38,000 (2009: loss of £41,000) * Number of debt management clients up to 4,216 (2009: 3,120) * Mortgage revenues decreased but operating profit increased due to cost cutting measures * Positive outlook with expectations of maiden profit for the full year

Michael Edelson, Chairman commented:

"I am very pleased that we have been able to generate a profit in the first half compared with the loss in the first half of the previous year.

"We continue to build the number of active debt management clients which is very encouraging. By focusing on the quality rather than the quantity of leads we hope to maintain the growth we have experienced in the last year.

"I remain hopeful that we will deliver a modest full year maiden profit".

Enquiries:Sterling Green Group plc Tel: 0161 975 5757Michael Edelson Merchant Securities Limited Tel: 020 7628 2200Simon Clements/David Worlidge CHAIRMAN'S STATEMENTIntroduction

I am pleased to present the Group's interim results for the six month period ended 30 September 2010.

Results and dividend

The Group generated a profit before and after taxation for the six month period of £38,000 (six months ended 30 September 2009: (loss) £41,000) on revenues of £1,322,000 (2009: £1,139,000). Earnings per share for the six month period were 0.01p (2009: 0.01p loss per share)

The Directors do not recommend the payment of a dividend.

Trading review

Debt management services

Revenues for the six month period were £1,258,000 (2009: £1,052,000) representing an increase of 20 per cent over the corresponding period in the previous year. This improvement was mainly due to an increase in the volume and quality of leads acquired from third parties. The improvement in the quality of the leads has led to a small decline in gross margins from 51 per cent to 47 per cent in the period but we remain confident that the current level of gross margin can be maintained as the Company grows.

Operating profits for the six month period were £133,000 (2009: £55,000) representing an increase of 142 per cent. The Board was able to reduce overheads in the debt management division during the period under review compared with the prior year principally due to savings in accommodation costs following renewal of the lease on the offices in central Manchester..

At 30 September 2010 the Group had 4,216 active debt management clients compared to 3,120 at 30 September 2009 and 3,335 at 31 March 2010, equivalent to an increase of 35 per cent over the last 12 months and 26 per cent in the last six months, respectively.

Re-mortgage services

Revenues for the six month period were £64,000 (2009: £87,000) a reduction of 26 per cent in the period. Operating profits have increased in the period to £ 18,000 (2009: £14,000) as the division was able to significantly reduce its operating costs.

Outlook

The mortgage market remains severely contracted and the Board does not envisage any significant upturn in revenues or profitability in this division for the foreseeable future. However, since this division makes a small positive contribution to the Group's results with minimum operating costs, the Board will continue to trade on the basis that current levels of activity are at the very least maintained.

The growth in new debt management clients since 31 March 2010 and the corresponding increase in revenues and profitability has been very encouraging. Accordingly, the Board believes that the Group is currently well positioned to deliver growth in shareholder value and is hopeful that the Group will be able to report a modest maiden profit for the full year to 31 March 2011.

Michael EdelsonChairman26 November 2010

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2010

Six months Six months Year ended 30 ended 30 ended 31 September September March 2010 2009 2010 (Unaudited) (Unaudited) (Audited) £000 £000 £000 Revenue 1,322 1,139 2,106 Cost of sales (692) (557) (1,128) Gross profit 630 582 978 Administrative expenses (565) (600) (1,143) Profit/(Loss) from operations 65 (18) (165) Finance costs (27) (23) (72) Profit/(Loss) on ordinary activities 38 (41) (237)before tax Income tax charge - - (1) Profit/(Loss) for the period and profit 38 (41) (238)/(loss) attributable to equity holders of the parent Earnings/(Loss) per share 0.01p (0.01p) (0.08p) Basic and diluted

There were no other items of comprehensive income other than the profit/(loss) for the period.

All amounts shown above relate to continuing operations.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2010

Six months Six months Year ended 30 ended 30 ended 31 September September March 2010 2009 2010 (Unaudited) (Unaudited) (Audited) £000 £000 £000 Balance at the beginning of the period 687 925 925 Total comprehensive income for the period Profit/(Loss) for the period 38 (41) (238) Balance at the end of the period 725 884 687

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2010 As at 30 As at 30 As at September September 31 March 2010 2009 2010 (Unaudited) (Unaudited) (Audited) £000 £000 £000 Non-current assets Goodwill 1,115 1,115 1,115 Property, plant and equipment 89 161 116 Total non-current assets 1,204 1,276 1,231 Current assets Trade and other receivables 226 235 108 Cash and cash equivalents 76 97 28 Total current assets 302 332 136 Total assets 1,506 1,608 1,367 Current liabilities Trade and other payables (340) (364) (361) Current tax liabilities - - (1) Borrowings (24) (86) (39) Total current liabilities (364) (450) (401) Net current liabilities (62) (118) (265) Non-current liabilities Borrowings (417) (274) (279) Total non-current liabilities (417) (274) (279) Total liabilities (781) (724) (680) Net assets 725 884 687 Equity Share capital 304 304 304 Share premium account 1,794 1,794 1,794 Capital reserve 6 6 6 Other reserves 891 891 891 Accumulated losses (2,270) (2,111) (2,308) Total equity 725 884 687

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2010

Six months Six months Year ended 30 ended 30 ended 31 September September March 2010 2009 2010 (Unaudited) (Unaudited) (Audited) £000 £000 £000 Cash flows (used in)/from operating activities Profit/(Loss) before tax 38 (41) (237) Adjustments for: Depreciation of property, plant and 31 49 98equipment Finance costs 27 23 72 Operating cash flows before movement in 96 31 (67)working capital

(Increase)/Decrease in trade and other (118) (93) 34 receivables

(Decrease)/Increase in trade and other (21) 45 42payables Corporation tax paid (1) - - Net cash (used in)/from operating (44) (17) 9activities Cash flow used in investing activities Purchase of property, plant and (4) (1) (5)equipment Net cash used in investing activities (4) (1) (5) Cash flow from/(used in) financing activities Capital element of finance lease (27) (44) (86)payments Proceeds from new loans 150 - - Finance costs (27) (23) (72) Net cash from/(used in) financing 96 (67) (158)activities Net increase/(decrease) in cash and 48 (85) (154)cash equivalents Cash and cash equivalents at the start 28 182 182of the period Cash and cash equivalents at the end of 76 97 28the period

NOTES TO THE HALF-YEARLY REPORT

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2010

1. Reporting entity

Sterling Green Group plc (the "Company") is a company incorporated in the United Kingdom under the Companies Act 2006. The interim results of the Company for the six month period ended 30 September 2010 comprise the Company and its subsidiaries (together the "Group").

The annual report and financial statements of the Group for the year ended 31 March 2010 are available upon request from the Company's registered office by writing to the Company Secretary, Sterling Green Group plc, Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport SK4 3GN or can be obtained from the Company's website which is www.sterlinggreen.co.uk.

2. Statement of compliance

These interim results have been prepared on the basis of the recognition and measurement requirements of IFRS anticipated to be in issue as either endorsed by the EU and effective (or available for early adoption) at 31 March 2011.

These interim results should be read in conjunction with the annual report and financial statements of the Group for the year ended 31 March 2010, which were approved for issue by the Board of Directors on 29 September 2010, as it provides an update on previously reported information. The comparative figures for the year ended 31 March 2010 are not the Group's statutory financial statements for the financial year. They are, however, derived from the statutory financial statements for that year which have been delivered to the Registrar of Companies. Those financial statements received an unqualified audit report which did not contain statements under sections 498 (2) or (3) of the Companies Act 2006.

These interim results were approved by the Board on 26 November 2010. The financial information contained therein for the six month period ended 30 September 2010, and similarly the six month period ended 30 September 2009, has neither been audited nor reviewed.

3. Significant accounting policies

The accounting policies used in the presentation of these interim results are consistent with those used in the annual report and financial statements of the Group for the year ended 31 March 2010.

4. Estimates

The preparation of interim results requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these interim results, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial statements of the Group for the year ended 31 March 2010.

5. Operating segments

The Group's business segments are its debt management division, its re-mortgaging operations and its head office operations. This is the basis on which the Group reports its primary segmental information. In the table below, all revenues are generated by sales to external parties.

Debt Re- Unallocated Total Management mortgages Group items £000 £000 £000 £000 Performance by activity: Revenue: - six months ended 30 1,258 64 - 1,322Sept 2010 - six months ended 30 1,052 87 - 1,139Sept 2009 - year ended 31 March 1,977 129 - 2,1062010 Operating profit/(loss): - six months ended 30 133 18 (86) 65Sept 2010 - six months ended 30 55 14 (87) (18)Sept 2009 - year ended 31 March 10 12 (187) (165)2010 Total assets: - 30 September 2010 1,494 5 7 1,506 - 30 September 2009 1,563 25 20 1,608 - 31 March 2010 1,358 6 3 1,367

The Group operates in a sector where no significant seasonal or cyclical variations in revenues and operating results are experienced during the financial year.

6. Earnings/(Loss) per share

The calculation of earnings/(loss) per share is based on the following:

Earnings/(Loss) Six months Six months Year ended 30 ended 30 ended 31 September September March 2010 2009 2010 Earnings/(loss) for the 38 (41) (238)purpose of basic and diluted earnings/(loss) per share being the net profit/(loss) attributable to equity holders of the parent (£000) Number of shares 303,500,527 303,587,719 303,675,390 Weighted average number of - -ordinary shares for the 12,227,723 purpose of basic earnings/ (loss) per share Effect of dilutive potential ordinary shares - share options Weighted average number of 315,903,113 303,500,527 303,587,719ordinary shares for the purpose of diluted earnings/ (loss) per share Earnings/(Loss) per share (pence) Basic 0.01 (0.01) (0.08) Diluted 0.01 (0.01) (0.08)

The Company's potential ordinary shares, which consist of share options, would not be dilutive in the comparative periods due to the losses incurred.

7. Dividends

No dividend is proposed for the six month period ended 30 September 2010. No dividend was paid in, or proposed for, the year ended 31 March 2010.

vendor
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.